Krystal Biotech (KRYS) Stock Price, News & Analysis

Company Overview

Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering. Vyjuvek was approved by the U.S. Food and Drug Administration in 2023 and is marketed in the United States.

Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech is also developing additional gene therapy candidates for rare dermatological, pulmonary and other genetic diseases. Its pipeline has included programs such as KB407 for cystic fibrosis and KB408 for alpha-1 antitrypsin deficiency. The company is led by President and Chief Executive Officer Krish S. Krishnan, who co-founded Krystal Biotech with Suma Krishnan.

Key Stats

• Today's Range: $346.68 to $354.24
• 50-Day Range: $312.57 to $375.40
• 52-Week Range: $141.24 to $382.54
• Volume: 206,263 shs
• Average Volume: 217,698 shs
• Market Capitalization: $10.27 billion
• P/E Ratio: 43.48
• Dividend Yield: N/A
• Price Target: $365.40
• Consensus Rating: Moderate Buy

Krystal Biotech Stock Analysis - MarketRank™

Krystal Biotech scored higher than 72% of companies evaluated by MarketBeat, and ranked 214th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Krystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Krystal Biotech is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Krystal Biotech has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 24.73%

Earnings Growth

Earnings for Krystal Biotech are expected to grow by 24.73% in the coming year, from $7.48 to $9.33 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Krystal Biotech is 43.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of Krystal Biotech is 43.48, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.94.

Price to Book Value per Share Ratio

Krystal Biotech has a P/B Ratio of 8.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.02% of the float of Krystal Biotech has been sold short.

Short Interest Ratio / Days to Cover

Krystal Biotech has a short interest ratio ("days to cover") of 15.27, which indicates bearish sentiment.

Change versus previous month

Short interest in Krystal Biotech has recently increased by 4.46%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Krystal Biotech does not currently pay a dividend.

Dividend Growth

Krystal Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 4.8 / 5
• News Sentiment: 1.66

News Sentiment

Krystal Biotech has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Krystal Biotech this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

7 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,558,270.00 in company stock.

Percentage Held by Insiders

13.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/13/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KRYS
• CIK: 1711279
• Web: www.krystalbio.com
• Phone: (412) 586-5830
• Fax: N/A
• Employees: 295
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Krystal Biotech: $365.40
• High Price Target: $474.00
• Low Price Target: $284.00
• Potential Upside/Downside: +5.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.98
• Trailing P/E Ratio: 43.48
• Forward P/E Ratio: 46.39
• P/E Growth: N/A
• Net Income: $204.83 million
• Net Margins: 54.82%
• Pretax Margin: 51.45%
• Return on Equity: 19.34%
• Return on Assets: 17.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.32
• Quick Ratio: 7.96

Sales & Book Value

• Annual Sales: $389.13 million
• Price / Sales: 26.40
• Cash Flow: $7.29 per share
• Price / Cash Flow: 47.60
• Book Value: $42.06 per share
• Price / Book: 8.25

Miscellaneous

• Outstanding Shares: 29,600,000
• Free Float: 25,722,000
• Market Cap: $10.27 billion
• Optionable: Optionable
• Beta: 0.54